Samsung Biologics Partners with Europe's Largest VC... "Supporting Customized Development"

Partnership Agreement with Kurma Partners
Strategic Collaboration with Bio and Healthcare VC

Samsung Biologics announced on the 24th that it has signed a partnership with global bio healthcare venture capital (VC) Kurma Partners to support the development and production of biopharmaceuticals for its portfolio companies.

Samsung Biologics Plant 3 exterior view.
[Photo by Samsung Biologics]

Under this agreement, Samsung Biologics will provide customized contract development services to biotech companies invested in by Kurma Partners. In particular, through the 'Customized CMC Solution' launched last August, it plans to offer programs tailored to the characteristics and development strategies of each candidate substance, enabling these companies to develop processes with optimized services from the early stages of development.

Kurma Partners, affiliated with Eurazeo, the largest investment group in Europe, is a venture capital firm specializing in investments in the bio healthcare sector since its establishment in 2009. Currently, it has secured an extensive network with pharmaceutical companies in major global bio clusters based on the European market.

Through this agreement, Samsung Biologics aims to increase cases of mutual growth with promising biotech companies as a global leader in contract development and manufacturing organization (CDMO), strengthening partnerships with potential clients. This will strategically enhance opportunities to provide Samsung Biologics’ end-to-end solutions?from contract development (CDO) to contract manufacturing (CMO), aseptic filling, and finishing processes?when partners succeed in biopharmaceutical development.

John Rim, President of Samsung Biologics, said, "We are pleased to support the growth of promising global biotech companies through collaboration with Kurma Partners. We will continue to innovate our services so that clients can reduce risks in biopharmaceutical development and enter the market more quickly through Samsung Biologics’ differentiated competitiveness and expertise."

Dr. Daniel Parera, Partner at Kurma Partners, said, "We are delighted to collaborate with Samsung Biologics, which leads the CDMO industry with world-class capabilities. Kurma Partners’ portfolio companies will greatly benefit from this partnership throughout the stages from biopharmaceutical development to market entry."

Meanwhile, Samsung Biologics entered the CDO business in 2018 and has signed over 100 contracts within five years. Recently, it launched the Customized Development Solution service, expanding process development services for candidate substances not only in the preclinical stage but also through late clinical stages, providing enhanced CDO services.

This content was produced with the assistance of AI translation services.